The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

(12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) <li /> EO ...

Adding tafasitamab to treatment with lenalidomide and rituximab improved outcomes in patients with relapsed or refractory follicular lymphoma.

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products ...

It is popularly said in this country that a politician out of power is like a ‘banana without skin’. These days, we see ...

On the orders of the Maligakanda Magistrate, to whom the Criminal Investigation Department (CID) is reporting evidence regarding this case, the NMRA sent vials from three batches of counterfeit ...

Approval was based on results from the Phase III inMIND trial, which demonstrated a statistically significant and clinically ...

Christina Poh, MD, discusses the recent FDA approval of tafasitamab plus lenalidomide and rituximab in relapsed/refractory ...

The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free ...

Background Despite case series suggesting efficacy, controlled trials of anti-CD20 in lupus and lupus nephritis (LN) have not meet their primary endpoints (Arthritis Rheum 2012;64:1215 and ...